linsitinib

DRUG9 trials

Conditions

Adenocarcinoma of the ProstateAdvanced Solid TumorsCarney ComplexChondrosarcomaEndocrine System DiseasesExophthalmosEye DiseasesGastrointestinal Stromal Tumor

Phase 1

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

WithdrawnNCT01465815

OHSU Knight Cancer InstituteRecurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin +3

Start: 2011-12-31End: 2013-09-30Updated: 2014-11-19

Phase 2

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

CompletedNCT01533246

National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer +1

Start: 2012-02-29End: 2012-11-30Updated: 2015-03-13

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

CompletedNCT01533181

National Cancer Institute (NCI)Recurrent Small Cell Lung Carcinoma

Start: 2012-02-29End: 2014-11-30Updated: 2016-01-14

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

CompletedNCT01560260

National Cancer Institute (NCI)Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor +1

Start: 2012-03-31End: 2015-10-31Updated: 2018-09-21

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

CompletedNCT02057380

Astellas Pharma Global Development, Inc.Advanced Solid Tumors

Start: 2014-04-16End: 2016-12-21Updated: 2024-11-20

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

CompletedNCT02546544

University of OxfordRefractory Ewing Sarcoma, Relapsed Ewing Sarcoma

Start: 2014-03-31End: 2016-07-15Updated: 2019-06-03

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

CompletedNCT05276063

Sling Therapeutics, Inc.Endocrine System Diseases, Exophthalmos, Eye Diseases +9

Start: 2022-07-01End: 2025-09-26Updated: 2026-08-26

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

RecruitingNCT06112340

Sling Therapeutics, Inc.Endocrine System Diseases, Exophthalmos, Eye Diseases +9

Start: 2023-10-11End: 2026-06-30Target: 75Updated: 2025-02-25

Phase 3

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

RecruitingNCT07753603

Sling Therapeutics, Inc.Graves Orbitopathy, Thyroid Eye Disease, TED

Start: 2026-08-04End: 2030-06-28Target: 130Updated: 2026-08-11

Related Papers

Treatment with linsitinib, an IGF-1 receptor inhibitor, attenuates disease development and progression in an experimental model of Graves’ Orbitopathy

The Journal of Immunology2023-05-01

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).

2018-02-2330 citations

Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).

Journal of Clinical Oncology2014-05-2017 citations